Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Capital Expenditures (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Capital Expenditures for 3 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 396.52% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $292000.0 through Dec 2025, down 54.52% year-over-year, with the annual reading at $292000.0 for FY2025, 54.52% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$1.9 million at Artiva Biotherapeutics, down from $600000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $1.1 million in Q2 2025, with the low at -$1.9 million in Q4 2025.
  • Average Capital Expenditures over 3 years is $88600.0, with a median of $264500.0 recorded in 2024.
  • Peak annual rise in Capital Expenditures hit 6933.33% in 2025, while the deepest fall reached 396.52% in 2025.
  • Over 3 years, Capital Expenditures stood at -$599000.0 in 2023, then soared by 205.51% to $632000.0 in 2024, then tumbled by 396.52% to -$1.9 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$1.9 million, $600000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.